CAP22 / Glycadia - LARVOL DELTA

"Poster @TheUSCAP #USCAP22 scrambling a last-minute project and getting it accepted is a success I guess! So excited! @SamKhader @PoojaSMD @dmcoconubo #cytopath #bstpath" (@Baskotacytopath)

SKAP2

"The @TheUSCAP abstract review committee is outstanding. So many anxious hearts waiting that decision on their #pathology abstract for #uscap22 @RhondaYantiss" (@Sinchita_Roy)

Review • SKAP2

"Sorry to have missed it but NOLA #CAP22 sounds fun! And there is always virtual catch up...." (@emckaymd)

"So great seeing everyone at #CAP21. 😁 Here’s to #CAP22 😉" (@NRiddleMD)

"One step at a time 👉#PathMatch22 😁😁 Missed #CAP21 so much 😭 Can't wait for #CAP22 to meet all you wonderful tweeple ☺️☺️" (@MdTushir)

"#uscap22 cannot wait @RhondaYantiss @TheUSCAP" (@Sinchita_Roy)

SKAP2

Clinical, cellular and molecular evidence of the additive antitumor effects of biguanides and statins in prostate cancer. (PubMed, J Clin Endocrinol Metab) - "Biguanides and statins significantly reduced tumor aggressiveness in PCa, being this effect more potent (in vitro and in vivo) when both compounds are combined. Therefore, given the demonstrated clinical safety of biguanides and statins, our results suggest a potential therapeutic role of these compounds, especially their combination, for the treatment of PCa."

Clinical • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AMPK • MYC

Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. (PubMed, EBioMedicine) - "These results demonstrate that the spliceosome is drastically altered in PCa wherein SNRNP200, SRSF3 and SRRM1 could represent attractive novel diagnostic/prognostic and therapeutic targets for PCa and CRPC."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. (PubMed, Dig Dis Sci) - "The diagnostic performance of CAP for any HS seems to be limited in patients with ACLD, if CSPH is present."

Clinical • Journal • Fibrosis • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension

Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children (ILC 2018) - "...All patients had CAP>225 indicating steatosis and 50% of female and 80% of male patients had severe steatosis with CAP>300 (Figure)... CAP/TE provides a reliable way to confirm the diagnosis of NAFLD and assess its severity in children. Larger pediatric studies that assess the correlation with liver histology and disease progression are urgently needed. The prevalence and severity of steatosis/fibrosis based on FibroscanTM measurements."

Clinical • Biosimilar • Cardiovascular • Diabetes • Fibrosis • Hypertension • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity

Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. (PubMed, Clin Gastroenterol Hepatol) - "LSM, LSPS, and portal hypertension risk score identify obese or overweight patients with cACLD who are at increased risk of decompensation and severe bacterial infection."

Clinical • Journal

Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. (PubMed, Turk J Gastroenterol) - "TE is a useful non-invasive imaging modality to screen for liver involvement in Turkish patients with T2DM. High rates of TE-defined fibrosis and steatosis in our sample reflect the presence of an elevated mean BMI."

Clinical • Journal

V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. (PubMed, Cell Rep) - "A cocrystal structure of CAP228-16H bound to a V2 peptide identified a IGLV3-21 gene-encoded DDxD motif that is used to bind K169, with a mechanism that allows CAP228-16H to recognize more globally relevant V2 immunotypes. Overall, these data further our understanding of the development of cross-reactive, V2-binding, antiviral antibodies and effectively expand the human light chain repertoire able to respond to RV144-like immunogens."

Journal

Fibroscan Is a Feasible and Useful Point-Of-Care Tool to Assess Nonalcoholic Fatty Liver Disease Severity in Children Texas Liver Institute, University of Texas (UT) Health San Antonio, San Antonio, TX (ACG 2019) - "15/116 (13%) of patients fell within the mild steatosis range (CAP 225-250), 31/116 (27%) with moderate steatosis (CAP 250-300) and the majority, 66/116 (57%), of patients having severe steatosis with CAP values > 300... 119 children with suspected NAFLD were referred to the clinic between May 2017 and April 2019. The mean age at time of assessment was 13.0 (± 3.0) years. The majority were males (68%), obese (87%) and of Hispanic ethnicity (77%)."

Clinical

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. (PubMed, J Clin Med) - "...Here, we analyzed 1) the expression/secretion profile of EN2 in five independent samples cohorts from PCa patients and controls (prostate tissues and/or urine) to determine its utility as a PCa biomarker; and 2) the functional role of EN2 in normal (RWPE1) and tumor (LNCaP/22Rv1/PC3) prostate cells to explore its potential value as therapeutic target...Consistently, EN2 treatment also regulated androgen-receptor activity (full-length and splicing variants) in androgen-sensitive 22Rv1 cells. Altogether, this study demonstrates the potential utility of EN2 as a non-invasive diagnostic biomarker for PCa and provides novel and valuable information to further investigate its putative utility to develop new therapeutic tools in PCa."

Biomarker • Journal

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. (PubMed, Mol Ther Methods Clin Dev) - "...To overcome these obstacles, adeno-associated virus (AAV) vectors were used to provide long-term expression of antibodies targeting the V2 region of the HIV-1 envelope protein, including the potent CAP256-VRC26.25 bNAb, as well as non-neutralizing CAP228 antibodies that resemble those elicited by vaccination...Secreted antibodies collected from serum retained the expected binding and neutralizing activity. The vectors generated here are, therefore, suitable for the delivery of V2-targeting HIV antibodies, and they could be used in a vectored immunoprophylaxis (VIP) approach to sustain the level of antibody expression required to prevent HIV infection."

Journal